Zobrazeno 1 - 10
of 457
pro vyhledávání: '"Anthony M. Marinaki"'
Autor:
Matthew Traylor, Jemma L Walker, Adele A Corrigan, Monica A Hernandez, Stephen J Newhouse, Amos A Folarin, Hamel Patel, Paul J Ross, Jeremy D Sanderson, James Spicer, Natalie J Prescott, Christopher G Mathew, Anthony M Marinaki, Cathryn M Lewis
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0188911 (2018)
Fluoropyrimidines, including 5-fluororacil (5FU) and its pro-drug Capecitabine, are the common treatment for colorectal, breast, neck and head cancers-either as monotherapy or in combination therapy. Adverse reactions (ADRs) to the treatment are comm
Externí odkaz:
https://doaj.org/article/6d940899bc9b491f95fee80b85b2107c
Autor:
Kay Ridgwell, Thomas Lynes, Jennifer Jolley, Anthony M. Marinaki, Peter A. Smethurst, Matthew Hazell, Sue Proffitt, Simon Procter, Phil Mellor, Rebecca Braund, Rebecca Cardigan, Redjuvenate Trial Investigators, Alexandra Griffiths, Gavin J. Murphy, Dave Edmondson, Helen V New
Publikováno v:
Transfusion. 59:2952-2963
Background Rejuvenation of stored red blood cells (RBCs) increases levels of adenosine 5'-triphosphate (ATP) and 2,3-diphosphoglycerate (2,3-DPG) to those of fresh cells. This study aimed to optimize and validate the US-approved process to a UK setti
Autor:
Chara Stavraka, Janine Mansi, Karen DeSouza, Anthony M. Marinaki, E. Karapanagiotou, Matthaios Kapiris, Athanasios Pouptsis, Leroy Okonta, Dionysis Papadatos-Pastos, Philip Charlton
Publikováno v:
Breast Cancer Research and Treatment
Purpose Metastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities. However, prospective DPYD genotyping has not yet bee
Publikováno v:
Oxford Textbook of Medicine
Disorders of purine and pyrimidine metabolism are due to abnormalities in the biosynthesis, interconversion, and degradation of the purines—adenine and guanine—and of the pyrimidines—cytosine, thymine, and uracil. The purine nucleotides, their
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02490c958612373ffc30cce517d3e105
https://doi.org/10.1093/med/9780198746690.003.0230
https://doi.org/10.1093/med/9780198746690.003.0230
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 50(1)
The thiopurine drugs azathioprine and mercaptopurine are effective in the treatment of disorders of immune regulation and acute lymphoblastic leukaemia. Although developed in the 1950s, thiopurines remained relevant in the anti-tumour necrosis factor
Autor:
Milena Ivanova, Dobromir Tanev, Tzvetan Alaikov, Parvoleta Peteva, Anthony M. Marinaki, Velizar Shivarov, Lynette D. Fairbanks
Publikováno v:
JCR: Journal of Clinical Rheumatology. 26:e49-e52
Autor:
Eleanor G. Seaby, Martina Živná, Stanislav Kmoch, Kateřina Hodaňová, Christine Gast, Sara Campbell, Daniel P. Gale, David J. Bunyan, Sarah Ennis, Gopalakrishnan Venkat-Raman, Thomas M. Connor, Reuben J. Pengelly, Anthony M. Marinaki, Monica Arenas-Hernandez
Publikováno v:
BMC Nephrology
BMC Nephrology, Vol 19, Iss 1, Pp 1-11 (2018)
BMC Nephrology, Vol 19, Iss 1, Pp 1-11 (2018)
Background Autosomal dominant tubulointerstitial kidney disease (ADTKD) caused by mutations in the UMOD gene (ADTKD-UMOD) is considered rare and often remains unrecognised. We aimed to establish the prevalence of genetic kidney diseases, ADTKD and AD
Publikováno v:
Personalized medicine. 3(1)
Genetic variation in thiopurine methyltransferase (TPMT) enzyme activity strongly predicts adverse effects in patients treated with the thiopurine drugs, azathioprine and 6-mercaptopurine, and is one of the classic examples of pharmacogenetics in cli
Publikováno v:
Personalized medicine. 9(7)
Thiopurines are an important class of immunosuppressive therapy, which have been used in clinical practice for over 50 years. Despite this extensive experience many of the pharmacodynamic and pharmacokinetic properties of these drugs remain unknown.
Autor:
Jemma L Walker, Christopher G. Mathew, A. Corrigan, Amos Folarin, Matthew Traylor, Natalie J. Prescott, Paul Ross, Stephen Newhouse, Hamel Patel, Monica Arenas Hernandez, Anthony M. Marinaki, James Spicer, Jeremy D. Sanderson, Cathryn M. Lewis
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 5, p e0188911 (2018)
Traylor, M, Walker, J L, Corrigan, A A, Hernandez, M A, Newhouse, S J, Folarin, A A, Patel, H, Ross, P J, Sanderson, J D, Spicer, J, Prescott, N J, Mathew, C G, Marinaki, A M & Lewis, C M 2018, ' Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer ', PLoS ONE, vol. 13, no. 5, e0188911 . https://doi.org/10.1371/journal.pone.0188911
PLoS ONE, Vol 13, Iss 5, p e0188911 (2018)
Traylor, M, Walker, J L, Corrigan, A A, Hernandez, M A, Newhouse, S J, Folarin, A A, Patel, H, Ross, P J, Sanderson, J D, Spicer, J, Prescott, N J, Mathew, C G, Marinaki, A M & Lewis, C M 2018, ' Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer ', PLoS ONE, vol. 13, no. 5, e0188911 . https://doi.org/10.1371/journal.pone.0188911
Fluoropyrimidines, including 5-fluororacil (5FU) and its pro-drug Capecitabine, are the common treatment for colorectal, breast, neck and head cancers—either as monotherapy or in combination therapy. Adverse reactions (ADRs) to the treatment are co